The 20 Best Midline Lethal Granuloma Doctors in The United States

Emmanouil Alimpertis is a Hematologist and an Oncologist practicing medicine in Marinette, Wisconsin. Dr. Alimpertis is rated as an Advanced provider by MediFind in the treatment of Midline Lethal Granuloma. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Neuroendocrine Tumor, Familial Prostate Cancer, Prostate Cancer, and Splenectomy. Dr. Alimpertis is board certified in American Board Of Internal Medicine, Hematology.

. Dr. Osterhus is rated as an Experienced provider by MediFind in the treatment of Midline Lethal Granuloma. He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Follicular Thyroid Cancer, Anaplastic Thyroid Cancer, Thyroid Cancer, Laryngectomy, and Septoplasty. Dr. Osterhus is board certified in American Board Of Otolaryngology.

Dr. Kyle Work joined the Cancer Centers of Colorado at St. Mary?s Medical Center oncology team in 2018. He is a hematologist-oncologist. Dr. Work treats all types of cancers with a special interest in head and neck cancer, lung cancer and genitourinary cancers.Dr. Work is originally from Tulsa, Oklahoma where he graduated from the University of Tulsa with a degree in biology, and earned his medical degree at Oklahoma State University. He then moved to Kansas City where he completed his internal medicine residency and hematology / oncology fellowship at the University of Kansas Health System. During his hematology and oncology fellowship, he served as chief fellow for two years.Dr. Work is an investigator involved in clinical research trials in the area of hematology and medical oncology. His clinical research focus includes head and neck cancers, brain and lung cancers. When he is not working, he enjoys mountain biking, camping, and hiking with his wife and golden retrievers. Dr. Work is rated as an Experienced provider by MediFind in the treatment of Midline Lethal Granuloma. He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Non-Small Cell Lung Cancer (NSCLC), and EGFR Positive Lung Cancer. Dr. Work is board certified in American Board Of Internal Medicine. Dr. Work is currently accepting new patients.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as a Distinguished provider by MediFind in the treatment of Midline Lethal Granuloma. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration. Dr. Ambinder is board certified in American Board Of Internal Medicine.

Jeffrey Thomas is a Hematologist and an Oncologist practicing medicine in Athens, Georgia. Dr. Thomas is rated as a Distinguished provider by MediFind in the treatment of Midline Lethal Granuloma. He is also highly rated in 165 other conditions, according to our data. His clinical expertise encompasses Midline Lethal Granuloma, Iron Deficiency Anemia, Essential Thrombocythemia, and Breast Cancer. Dr. Thomas is board certified in American Board Of Internal Medicine - Hematology and American Board Of Internal Medicine - Medical Oncology. Dr. Thomas is currently accepting new patients.

Triple board-certified in internal medicine, hematology and medical oncology, Dr. Mohamad Cherry is medical director of Hematology at Atlantic Health System. He joins Atlantic Hematology Oncology from the University of Oklahoma Health Sciences Center's Stephenson Cancer Center, bringing years of clinical knowledge and expertise.With specialty training from some of the nation's most skilled clinicians, Dr. Cherry attained some of his clinical training at the leukemia department at MD Anderson and his fellowship in hematology/oncology from the University of Oklahoma Health Sciences Center's Stephenson Cancer Center. He performed two residencies - an internal medicine residency at Staten Island University Hospital and a laboratory medicine residency at the American University of Beirut Medical Center in Lebanon. Previously, Dr. Cherry attained his medical degree at Lebanese University and performed his internship at Sacre Coeur Hospital-Lebanese University. He also earned a master of science degree in clinical and translational research from University of Oklahoma College of Public Health.Dr. Cherry remains on staff as clinical associate professor of hematology/oncology at University of Oklahoma Health Sciences Center's Stephenson Cancer Center. He is also the director of its hematology/oncology fellowship program and co-chairs the Academy of Teaching Scholars Faculty Development, Education and Mentoring Committee. Other administrative roles include co-chair of the leukemia working group at the Sarah Cannon Research Institute Blood Cancer Consortium.As a principal investigator of multiple clinical trials, Dr. Cherry has performed groundbreaking research in niche areas that include epigenetics and development of new therapeutics in relapsed and refractory blood cancers. He has developed teaching materials and book chapters, and has lectured both nationally and internationally.Dr. Cherry continues to serves as a mentor and an advisor to fellows, residents and medical students. He contributes to continuing education, public health, and professional development, and has won awards and funding for both his research and his clinical pursuits. Dr. Cherry is rated as a Distinguished provider by MediFind in the treatment of Midline Lethal Granuloma. He is also highly rated in 44 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Acute Myeloblastic Leukemia without Maturation, Midline Lethal Granuloma, and Bone Marrow Aspiration. Dr. Cherry is board certified in American Board Of Internal Medicine. Dr. Cherry is currently accepting new patients.

. Dr. Farwell is rated as an Experienced provider by MediFind in the treatment of Midline Lethal Granuloma. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Liposarcoma, Mesenchymoma, Undifferentiated Pleomorphic Sarcoma, and Fibrosarcoma. Dr. Farwell is board certified in American Board Of Nuclear Medicine and American Board Of Radiology.

. Dr. Scanlon is rated as an Experienced provider by MediFind in the treatment of Midline Lethal Granuloma. She is also highly rated in 3 other conditions, according to our data. Her clinical expertise encompasses Colonic Malakoplakia, Pleural Effusion, Pleurisy, and Subcutaneous Emphysema. Dr. Scanlon is board certified in American Board Of Radiology.

. Dr. Pantel is rated as an Experienced provider by MediFind in the treatment of Midline Lethal Granuloma. He is also highly rated in 1 other condition, according to our data. His clinical expertise encompasses Neuroendocrine Tumor, Classical Hodgkin Lymphoma, Lung Nodules, Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), and Liver Embolization. Dr. Pantel is board certified in American Board Of Nuclear Medicine and American Board Of Radiology.

John Plastaras is a Radiation Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Plastaras is rated as a Distinguished provider by MediFind in the treatment of Midline Lethal Granuloma. He is also highly rated in 49 other conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, T-Cell Lymphoma, Mediastinal Tumor, and Midline Lethal Granuloma. Dr. Plastaras is board certified in Radiation Oncology, 2008. Dr. Plastaras is currently accepting new patients.

Ara Chalian is an Otolaryngologist practicing medicine in Philadelphia, Pennsylvania. Dr. Chalian is rated as a Distinguished provider by MediFind in the treatment of Midline Lethal Granuloma. He is also highly rated in 40 other conditions, according to our data. His clinical expertise encompasses Salivary Gland Tumors, Acinic Cell Carcinoma of Salivary Glands, Tongue Cancer, Thyroidectomy, and Gastrostomy. Dr. Chalian is board certified in Otolaryngology, 1994. Dr. Chalian is currently accepting new patients.

Julie Vose is a Hematologist and an Oncologist practicing medicine in Omaha, Nebraska. She has been practicing medicine for over 42 years. Dr. Vose is rated as an Experienced provider by MediFind in the treatment of Midline Lethal Granuloma. She is also highly rated in 34 other conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Todd Barnett is a multiple time recipient of the Seattle Top Doctor Award and most recently received the 2024 Seattle Magazine Top Doc Award. Dr. Barnett earned his medical degree from Northwestern University, Chicago, Ill. He completed his residency and fellowship at Stanford University, Calif. Dr. Barnett is rated as an Experienced provider by MediFind in the treatment of Midline Lethal Granuloma. He is also highly rated in 2 other conditions, according to our data. His clinical expertise encompasses Familial Pancreatic Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Thyroid Cancer. Dr. Barnett is board certified in American Board Of Radiology. Dr. Barnett is currently accepting new patients.

Kanwaldeep Rasila is an Oncologist practicing medicine in Fairfield, California. Dr. Rasila is rated as an Advanced provider by MediFind in the treatment of Midline Lethal Granuloma. She is also highly rated in 55 other conditions, according to our data. Her clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Intraductal Papilloma, and Subacute Combined Degeneration. Dr. Rasila is board certified in Medical Oncology - Board Certified and Hematology - Board Certified. Dr. Rasila is currently accepting new patients.

Akash Mukherjee is a Hematologist and an Oncologist practicing medicine in Cincinnati, Ohio. Dr. Mukherjee is rated as an Advanced provider by MediFind in the treatment of Midline Lethal Granuloma. He is also highly rated in 48 other conditions, according to our data. His clinical expertise encompasses Large-Cell Immunoblastic Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Mukherjee is board certified in American Board Of Internal Medicine. Dr. Mukherjee is currently accepting new patients.

Seyfettin Alpdogan is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Alpdogan is rated as an Advanced provider by MediFind in the treatment of Midline Lethal Granuloma. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Cutaneous T-Cell Lymphoma (CTCL), Multiple Myeloma, and Bone Marrow Aspiration. Dr. Alpdogan is currently accepting new patients.

Blake Kimbrell is an Otolaryngologist practicing medicine in Athens, Georgia. Dr. Kimbrell is rated as an Advanced provider by MediFind in the treatment of Midline Lethal Granuloma. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Mikulicz Disease, Nonsyndromic Hearing Loss, Deafness Hypogonadism Syndrome, Infant Hearing Loss, and Myringotomy. Dr. Kimbrell is board certified in American Board Of Otolaryngology. Dr. Kimbrell is currently accepting new patients.

Sirisha Jain, MD, is a board-certified hematologist/oncologist with Harrison HealthPartners. Dr. Jain's goal is to, in this time of rapid growth of oncology treatments, with new research being published weekly, incorporate the latest treatments into her practice and stay current on the research. She hopes to form a partnership with her patients where she can help them navigate the information and difficult choices a cancer diagnosis brings. Dr. Jain believes it is vital for the health of her patients to focus on treating the whole person and not just the cancer diagnosis. Dr. Jain is rated as an Advanced provider by MediFind in the treatment of Midline Lethal Granuloma. She is also highly rated in 78 other conditions, according to our data. Her clinical expertise encompasses Angiosarcoma, Paget Disease of the Breast, Inflammatory Breast Cancer, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration. Dr. Jain is board certified in Hematology, Internal Medicine, and Medical Oncology. Dr. Jain is currently accepting new patients.

Jihua Cheng is a Hematologist Oncology provider practicing medicine in Harrisburg, Pennsylvania. Dr. Cheng is rated as an Advanced provider by MediFind in the treatment of Midline Lethal Granuloma. He is also highly rated in 47 other conditions, according to our data. His clinical expertise encompasses Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Anemia, and Pulmonary Embolism.

Erik Cohen, MD, FACS Erik Cohen, MD is the Medical Director of Head and Neck Oncologic Surgery at Morristown Medical Center and is also Clinical Director of the Leonard B Khan Head and neck Cancer Institute at Morristown Medical Center's Carol G. Simon Cancer Center. He is trained in Otolaryngology-Head and Neck Surgery (ear, nose, and throat surgery) and fellowship trained in Head and Neck Oncologic Surgery.Dr. Cohen manages patients with benign and malignant head neck tumors of the head and neck. This includes cancers of the mouth, throat, larynx and HPV-associated oropharynx cancer. He also specializes in management of benign and malignant tumors of the thyroid and parathyroid glands, salivary gland surgery including parotidectomy with facial nerve preservation, nasal cavity and paranasal sinus tumors, complex skin cancer surgery, and skull base surgery. He is experienced in minimally invasive approaches, including transoral robotic surgery (TORS) as well as endoscopic CO2 laser surgery.Dr. Cohen attended Medical School at the Albert Einstein College of Medicine in New York. He completed his residency training in Otolaryngology-Head and Neck Surgery at Temple University Hospital in Philadelphia, and a fellowship in Head and Neck Oncologic Surgery at Memorial Sloan Kettering Cancer Center in New York City. He was a faculty member at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School prior to joining Morristown Medical Center and the Atlantic Health System in 2012. He is a past president of the New York Head and Neck Society and an active member of several professional societies. Dr. Cohen is rated as an Advanced provider by MediFind in the treatment of Midline Lethal Granuloma. He is also highly rated in 34 other conditions, according to our data. His clinical expertise encompasses Acinic Cell Carcinoma of Salivary Glands, Salivary Gland Tumors, Laryngeal Cancer, Thyroidectomy, and Gastrostomy. Dr. Cohen is board certified in American Board Of Otolaryngology - Head And Neck Surgery. Dr. Cohen is currently accepting new patients.